Category: WFN1 Contributors

1239710 / 964 POSTS
By Brian Marckx, CFANASDAQ:MYOSREAD THE FULL MYOS RESEARCH REPORTQ1 2019 Update: MYOS Canine Sales Jump, Initial Reviews are Highly Encouraging. New QoL Dog Study Planned…MYOS RENS Technology Inc (NASDAQ:MYOS) reported Q1’19 financial results and pro ...
By John Vandermosten, CFANASDAQ:AZRXOn May 20th AzurRx BioPharma, Inc. (NASDAQ:AZRX) presented secondary endpoint results for its Phase II Chronic Pancreatitis (CP) study, which completed clinical work in June 2018. The update follows topline and pri ...
By Brian Marckx, CFANYSE:VNRXREAD THE FULL VNRX RESEARCH REPORTQ1 Results / Operational and Business Update:On May 9th VolitionRx (NYSE:VNRX) reported financial results for their fiscal 2019 first quarter ending March 31st. Operating expenses, at $4. ...
By David Bautz, PhDNASDAQ:SNGXREAD THE FULL SNGX RESEARCH REPORTBusiness UpdateEnrollment Target Reached for Interim Analysis of SGX942 Phase 3 TrialOn April 18, 2019, Soligenix, Inc. (NASDAQ:SNGX) announced that it has reached the enrollment target ...
By David Bautz, PhDNASDAQ:INMBREAD THE FULL INMB RESEARCH REPORTWe recently initiated coverage of INmune Bio, Inc. (NASDAQ:INMB) with a $19 valuation. INmune is a biopharmaceutical company developing therapies that target the innate immune system to ...
We all wish every lead turned into a great prospect and in less time. You probably also want it all to take you less time than it takes to decide what you want to eat for lunch. That would be the greatest customer, right? Yes, in a perfect world, tha ...
By David Bautz, PhDNASDAQ:BCLIREAD THE FULL BCLI RESEARCH REPORTBusiness UpdateData Presented at AAN Provides Additional Details on NurOwn®During the 71st American Academy of Neurology (AAN), BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) presented ...
By Brian Marckx, CFANASDAQ:ARWRREAD THE FULL ARWR RESEARCH REPORTPipeline Highlights: AAT Ph2/3 Trial Design, AAT and HBV EASL Presentations, Dosing Starts in ARO-ANG3/APOC3 Ph 1sArrowhead Pharmaceuticals (NASDAQ:ARWR) continues to make rapid progres ...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTFor Q1 2019, Chicken Soup for the Soul Entertainment's (NASDAQ:CSSE) revenues were $2.5 million versus $6.0 million a year ago, down 58%. Revenues and earnings missed expectations as the co ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateR&D Symposium Highlights Positive Exebacase DataOn May 14, 2019, ContraFect Corp. (NASDAQ:CFRX) held an R&D symposium on the potential for direct lytic agents (lys ...
1239710 / 964 POSTS